Reduced blood glucose levels by the combination of vadadustat in an elderly patient with chronic kidney disease who was receiving mitiglinide and sitagliptin: a case report.

Ayumi TakakuraToshinori HiraiNaomi HamaguchiRika MukoharaKazutaka MatsumotoYutaka YanoTakuya Iwamoto

Published in: Journal of pharmaceutical health care and sciences (2023)

Hypoglycemia was observed when sitagliptin, mitiglinide, and vadadustat were concomitantly administered, which may have resulted in a drug-drug interaction between vadadustat and sitagliptin via OAT3 inhibition in the renal tubules.

Keyphrases

blood glucose
chronic kidney disease
glycemic control
type diabetes
end stage renal disease
case report
adverse drug
middle aged
emergency department
metabolic syndrome
insulin resistance